Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | 9-ING-41 + Gemcitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
9-ING-41 | 9 ING 41|Elraglusib | GSK-3beta Inhibitor 4 | 9-ING-41 is an ATP-competitive inhibitor that selectively blocks GSK-3beta, potentially leading to cell cycle arrest and apoptosis, and antitumor effects including inhibition of cell proliferation and tumor growth (PMID: 31894292, PMID: 29846250). | |
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03678883 | Phase Ib/II | 9-ING-41 + Carboplatin + Paclitaxel 9-ING-41 + Irinotecan 9-ING-41 + Doxorubicin 9-ING-41 + Lomustine 9-ING-41 + Carboplatin 9-ING-41 + Gemcitabine + Nab-paclitaxel 9-ING-41 9-ING-41 + Gemcitabine | 9-ING-41 in Patients With Advanced Cancers | Recruiting | USA | ESP | 1 |